Adaptimmune gains on early liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $1.73 (19%) to $10.94 on Thursday after reporting that its

Read the full 155 word article

User Sign In